Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
The toxicity, function and mechanism of lycorine (LY) on osteosarcoma were accessed in vitro by CCK-8 assay, flow cytometry and western blotting and in vivo by the xenograft osteosarcoma mouse model.
|
31464976 |
2020 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
The function of miR-765 was investigated through Cell Counting Kit-8 (CCK-8) and transwell assays in OS.
|
31210288 |
2019 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
CCK-8 and flow cytometry assays were carried out to detect the proliferation and apoptosis of osteosarcoma cells.
|
31421084 |
2019 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, cytotoxicity was evaluated by cell viability assay and cell adhesion using human osteosarcoma cells (MG-63) and cell counter kit-8 (CCK-8) assay.
|
29853100 |
2018 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
CCK-8 and transwell assay showed that miR-31 inhibited osteosarcoma cells proliferation, migration, and invasion.
|
30468462 |
2018 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
CCK-8, Edu, and clone formation assays; wound healing and Transwell assays; PCR; immunohistochemistry; immunofluorescence; and western blotting were used to investigated the responses in TSSC3-overexpressing osteosarcoma cell lines, and in xenografts and metastasis in vivo models, with or without autophagy deficiency caused by chloroquine or ATG5 silencing.
|
30092789 |
2018 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, CCK-8 and colony formation assays indicated that miR-491-5p mimics suppressed OS cell proliferation.
|
30405785 |
2018 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
The biological functions of miR-127-3p and ITGA6 in OS were investigated by following experiments: cell counting kit 8 (CCK-8) and colony formation assays to inspect cell proliferation, flow cytometry, and caspase 3 activity assay to examine apoptosis, and transwell and wound healing assays to analyze invasion and migration.
|
29573114 |
2018 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
CCK-8 assay was employed to detect the proliferation of osteosarcoma cells, while transwell assays were used to examine the migration and invasion.
|
28882648 |
2017 |
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Based on WST-8 assay with CCK-8, in general, the newly synthesized dichloroplatinum complexes 1-6 showed higher in vitro antitumor activity than platinum-free compounds L1-L6 against three tumor cell lines (especially osteosarcoma MG-63).
|
28082035 |
2017 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, human osteoblast-like osteosarcoma cells MG63 and human mesenchymal stem cells were seeded on the glass beads to determine their cytocompatibility via applying CCK assay, ALP assay and Ca assay.
|
28762960 |
2017 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Altogether, the Cell Counting Kit-8 (CCK-8), the colony formation, the flow cytometry and the Transwell assay results demonstrated that miR-504 promoted osteosarcoma cell growth and metastasis in vitro.
|
29048685 |
2017 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
CCK-8 and colony forming assays showed that proliferation in OS cell lines was downregulated when siRNA was used to knockdown CARM1 expression.
|
28924379 |
2017 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effects of ectopic miR-497 expression on the cell survival and cisplatin sensitivity in osteosarcoma cells were measured by the Cell Counting Kit-8 (CCK-8) assay.
|
26202364 |
2015 |